Enovis (ENOV) Jefferies London Healthcare Conference 2024 summary

Company transformation and strategic direction

• Transitioned from a diversified industrial to a focused MedTech company through divestitures and acquisitions, notably DJO and Lima.

• Portfolio now balanced between reconstructive surgery (Recon) and prevention & recovery (P&R), each contributing about $1 billion in revenue.

• Strategic focus on high single-digit organic growth, margin expansion, and bolt-on acquisitions to accelerate growth.

• Recon business expanded significantly through acquisitions, now positioned for high single- to double-digit growth.

• Company has become more global, with a stronger presence in foot and ankle and improved P&R growth.

Financial performance and outlook

• Targets high single-digit organic growth, outpacing market averages of 4%-5%.

• Recon business historically grows double digits; P&R grows 3%-4%.

• EBITDA margin has improved from 14% in 2022 to about 18% in 2024, with a clear path to 20%+.

• Margin expansion driven by positive business mix, acquisition synergies, and continuous productivity improvements.

• Expects at least 50 basis points of margin expansion annually, with some years seeing outsized gains.

Acquisition strategy and integration

• Over 20 acquisitions in recent years, with Lima being the largest and most transformational.

• Lima integration tracking at or above goals, with $10–15 million in cost savings expected this year and $40 million+ over time.

• Integration challenges largely behind, with focus shifting to cost and cross-selling synergies.

• Leverage remains high but manageable; smaller bolt-on deals likely in near term, with larger deals possible as leverage decreases.

• M&A activity will remain aligned with strategic growth and margin expansion objectives.